Last reviewed · How we verify

Ethris GmbH — Portfolio Competitive Intelligence Brief

Ethris GmbH pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Addpharma Inc. · 1 shared drug class
  2. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
  3. Beijing Minhai Biotechnology Co., Ltd · 1 shared drug class
  4. Biota Scientific Management Pty Ltd · 1 shared drug class
  5. Cocrystal Pharma, Inc. · 1 shared drug class
  6. IRCCS San Raffaele · 1 shared drug class
  7. Icahn School of Medicine at Mount Sinai · 1 shared drug class
  8. National Taiwan University Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ethris GmbH:

Cite this brief

Drug Landscape (2026). Ethris GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ethris-gmbh. Accessed 2026-05-15.

Related